Pharmacokinetics of meso-2,3- dimercaptosuccinic acid in patients with lead poisoning and in healthy adults

Richard C. Dart, Katherine M. Hurlbut, Richard M. Maiorino, Michael Mayersohn, H. Vasken Aposhian, Leslie V Boyer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

We compared the pharmacokinetics of meso-2,3-dimercaptosuccinic acid (DMSA) in three children with lead poisoning, three adults with lead poisoning, and five healthy adult volunteers. All subjects received DMSA orally. Maximum blood concentration and time to maximum blood concentration of total DMSA concentration were not statistically different among the groups. Unaltered DMSA was detected in the blood of all poisoned patients but in only one of five healthy volunteers. Elimination half-life of total DMSA (parent drug plus oxidized metabolites) was longer in children with lead poisoning (3.0 ± 0.2 hours) than in adults with lead poisoning (1.9 ± 0.4 hours) and healthy adults (2.0 ± 0.2 hours). Renal clearance of total DMSA was greater in healthy adults (77.0 ± 13.2 ml/min per square meter) than in either adults (24.7 ± 3.3 ml/min per square meter) or children with lead poisoning (16.6 ml/min per square meter); renal clearance of the metabolites of DMSA was also greater in healthy adults (64.6 ± 10.1 ml/min per square meter) than in either adults (35.4 ± 8.4 ml/min per square meter) or children with lead poisoning (19.5 ml/min per square meter). The DMSA appeared to enter the erythrocytes of patients with lead poisoning to a greater extent than in healthy adults. We conclude that renal clearance of DMSA and its metabolites may be impaired and that the distribution of DMSA in children with lead poisoning may be different from that in adults. (J PEDIATR 1994;125:309-16).

Original languageEnglish (US)
Pages (from-to)309-316
Number of pages8
JournalThe Journal of Pediatrics
Volume125
Issue number2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Succimer
Lead Poisoning
Pharmacokinetics
Kidney
Healthy Volunteers
Half-Life
Erythrocytes
Parents

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Pharmacokinetics of meso-2,3- dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. / Dart, Richard C.; Hurlbut, Katherine M.; Maiorino, Richard M.; Mayersohn, Michael; Aposhian, H. Vasken; Boyer, Leslie V.

In: The Journal of Pediatrics, Vol. 125, No. 2, 1994, p. 309-316.

Research output: Contribution to journalArticle

Dart, Richard C. ; Hurlbut, Katherine M. ; Maiorino, Richard M. ; Mayersohn, Michael ; Aposhian, H. Vasken ; Boyer, Leslie V. / Pharmacokinetics of meso-2,3- dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. In: The Journal of Pediatrics. 1994 ; Vol. 125, No. 2. pp. 309-316.
@article{472b9aff509042339be8db863f19212e,
title = "Pharmacokinetics of meso-2,3- dimercaptosuccinic acid in patients with lead poisoning and in healthy adults",
abstract = "We compared the pharmacokinetics of meso-2,3-dimercaptosuccinic acid (DMSA) in three children with lead poisoning, three adults with lead poisoning, and five healthy adult volunteers. All subjects received DMSA orally. Maximum blood concentration and time to maximum blood concentration of total DMSA concentration were not statistically different among the groups. Unaltered DMSA was detected in the blood of all poisoned patients but in only one of five healthy volunteers. Elimination half-life of total DMSA (parent drug plus oxidized metabolites) was longer in children with lead poisoning (3.0 ± 0.2 hours) than in adults with lead poisoning (1.9 ± 0.4 hours) and healthy adults (2.0 ± 0.2 hours). Renal clearance of total DMSA was greater in healthy adults (77.0 ± 13.2 ml/min per square meter) than in either adults (24.7 ± 3.3 ml/min per square meter) or children with lead poisoning (16.6 ml/min per square meter); renal clearance of the metabolites of DMSA was also greater in healthy adults (64.6 ± 10.1 ml/min per square meter) than in either adults (35.4 ± 8.4 ml/min per square meter) or children with lead poisoning (19.5 ml/min per square meter). The DMSA appeared to enter the erythrocytes of patients with lead poisoning to a greater extent than in healthy adults. We conclude that renal clearance of DMSA and its metabolites may be impaired and that the distribution of DMSA in children with lead poisoning may be different from that in adults. (J PEDIATR 1994;125:309-16).",
author = "Dart, {Richard C.} and Hurlbut, {Katherine M.} and Maiorino, {Richard M.} and Michael Mayersohn and Aposhian, {H. Vasken} and Boyer, {Leslie V}",
year = "1994",
doi = "10.1016/S0022-3476(94)70217-9",
language = "English (US)",
volume = "125",
pages = "309--316",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of meso-2,3- dimercaptosuccinic acid in patients with lead poisoning and in healthy adults

AU - Dart, Richard C.

AU - Hurlbut, Katherine M.

AU - Maiorino, Richard M.

AU - Mayersohn, Michael

AU - Aposhian, H. Vasken

AU - Boyer, Leslie V

PY - 1994

Y1 - 1994

N2 - We compared the pharmacokinetics of meso-2,3-dimercaptosuccinic acid (DMSA) in three children with lead poisoning, three adults with lead poisoning, and five healthy adult volunteers. All subjects received DMSA orally. Maximum blood concentration and time to maximum blood concentration of total DMSA concentration were not statistically different among the groups. Unaltered DMSA was detected in the blood of all poisoned patients but in only one of five healthy volunteers. Elimination half-life of total DMSA (parent drug plus oxidized metabolites) was longer in children with lead poisoning (3.0 ± 0.2 hours) than in adults with lead poisoning (1.9 ± 0.4 hours) and healthy adults (2.0 ± 0.2 hours). Renal clearance of total DMSA was greater in healthy adults (77.0 ± 13.2 ml/min per square meter) than in either adults (24.7 ± 3.3 ml/min per square meter) or children with lead poisoning (16.6 ml/min per square meter); renal clearance of the metabolites of DMSA was also greater in healthy adults (64.6 ± 10.1 ml/min per square meter) than in either adults (35.4 ± 8.4 ml/min per square meter) or children with lead poisoning (19.5 ml/min per square meter). The DMSA appeared to enter the erythrocytes of patients with lead poisoning to a greater extent than in healthy adults. We conclude that renal clearance of DMSA and its metabolites may be impaired and that the distribution of DMSA in children with lead poisoning may be different from that in adults. (J PEDIATR 1994;125:309-16).

AB - We compared the pharmacokinetics of meso-2,3-dimercaptosuccinic acid (DMSA) in three children with lead poisoning, three adults with lead poisoning, and five healthy adult volunteers. All subjects received DMSA orally. Maximum blood concentration and time to maximum blood concentration of total DMSA concentration were not statistically different among the groups. Unaltered DMSA was detected in the blood of all poisoned patients but in only one of five healthy volunteers. Elimination half-life of total DMSA (parent drug plus oxidized metabolites) was longer in children with lead poisoning (3.0 ± 0.2 hours) than in adults with lead poisoning (1.9 ± 0.4 hours) and healthy adults (2.0 ± 0.2 hours). Renal clearance of total DMSA was greater in healthy adults (77.0 ± 13.2 ml/min per square meter) than in either adults (24.7 ± 3.3 ml/min per square meter) or children with lead poisoning (16.6 ml/min per square meter); renal clearance of the metabolites of DMSA was also greater in healthy adults (64.6 ± 10.1 ml/min per square meter) than in either adults (35.4 ± 8.4 ml/min per square meter) or children with lead poisoning (19.5 ml/min per square meter). The DMSA appeared to enter the erythrocytes of patients with lead poisoning to a greater extent than in healthy adults. We conclude that renal clearance of DMSA and its metabolites may be impaired and that the distribution of DMSA in children with lead poisoning may be different from that in adults. (J PEDIATR 1994;125:309-16).

UR - http://www.scopus.com/inward/record.url?scp=0027963574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027963574&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(94)70217-9

DO - 10.1016/S0022-3476(94)70217-9

M3 - Article

C2 - 8040783

AN - SCOPUS:0027963574

VL - 125

SP - 309

EP - 316

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -